纳塔栎和柳叶栎对铅锌矿区污染土壤的修复潜力分析:田间试验

通过野外调查、采样和实验室分析方法,研究优新景观树种纳塔栎（Quercus nuttallii）和柳叶栎（Quercus phellos）对湖南郴州Pb、Zn矿区复合污染土壤的适应性和修复潜力。试验设计A、B、E区种植1年生纳塔栎,C、D区种植1年生柳叶栎,1年后测量株高、地径、生物量等生长指标,随机采集植物全株及根际土壤,测试植物根际土壤和树木组织中的重金属含量。试验结果：Pb、Zn矿区土壤受到重金属Cd、Pb、Zn和As的复合污染,不同区域的土壤表现出污染异质性,采用单污染指数（Pi）和内梅罗指数（P_N）评价不同地块的污染程度,A区尾矿库（P_N=20.08）和B区（P_N=3.14）为重度复合污染,C区（P_N=2.43）为中度复合污染,D区（P_N=1.55）和E区（P_N=1.07）为轻微污染。纳塔栎和柳叶栎在以上不同污染地块均能正常生长,株高、地径和生物量与复合污染指数（内梅罗指数）及重金属含量呈负相关。其中纳塔栎对Cd的生物富集系数（BCF）在A、B、E区分别为6.27-8.37、3.67-4.38、42.93-52.75,高于C、D区柳叶栎对Cd的生物富集系数1.79-2.15、0.89-1.07。B-E区Zn的转运系数（TF）在1.79-2.28之间,A区Zn的转运系数为0.43。结论：纳塔栎和柳叶栎表现出较强的重金属耐性,对Cd具有较高的生物富集能力,对Zn具有较高的转运能力。其中纳塔栎对重金属积累能力较强,可作为亚热带地区铅锌矿区Cd、Pb、Zn、As复合污染土壤的植被恢复及生态修复候选树种。     

单胺氧化酶抑制剂在临床方面的应用

单胺氧化酶（monoamine oxidase, MAO）是人体内天然存在的一种酶,催化单胺类物质氧化脱氨反应的酶。人体内含有两种单胺氧化酶：单胺氧化酶A 和单胺氧化酶B。单胺氧化酶A 主要分布在儿茶酚胺能神经元中;单胺氧化酶B 主要分布在5- 羟色胺能神经元、组胺能神经元和神经胶质细胞中,这两种亚型都均可以使单胺类神经递质失活。而单胺氧化酶抑制剂则能够通过抑制单胺氧化酶的对单胺类物质的氧化活性,从而达到减轻或者消除由各种原因引起的单胺类物质减少或单胺氧化酶活性过高导致的疾病。本文主要总结了近几年单胺氧化酶抑制剂在临床上用于治疗帕金森病、抑郁症和幽门螺旋杆菌方面的最新进展。     

红莲型细胞质雄性不育水稻线粒体atp6基因转录本的编辑位点研究

以红莲（HL）型水稻细胞质雄性不育系A、保持系B及杂种一代F₁为材料,首次比较研究了红莲型水稻线粒体atp6基因转录本的编辑位点及各位点的编辑频率.结果表明atp6基因的转录本有18个编辑位点,其中有15个发生在密码子的第一和第二位点上,这些位点的编辑最终会导致氨基酸种类的变化.18个编辑位点在A、B和F₁中没有差异,但各位点的编辑频率在引入了核恢复基因的条件下发生了较大的变化,完全编辑的比例增加.这些结果首次证明HL型细胞质雄性不育与线粒体atp6转录本的编辑有一定相关性,编辑不充分的转录产物最终会干扰线粒体功能的正常发挥.     

鼠mPC-1基因的克隆与特性分析

为深入研究人前列腺癌相关基因PC-1的生物功能和进化保守状况,从小鼠肾脏中克隆了全长cDNA序列,命名为mPC-1（GenBank Acc No.AY048852）.mPC-1基因cDNA全长为2 193 bp,主要定位于小鼠染色体3A1-A2区域.mPC-1基因最大开放阅读框编码的蛋白质由224个氨基酸组成,与人PC-1蛋白编码区存在82%的序列一致性,含有coiled-coil结构域和PEST结构域.生物信息学分析表明,由6个外显子组成的mPC-1基因与mD52高度同源,其中,第一外显子代表该基因的特异性序列,实验证据显示mPC-1基因具有自己的启动子,推测mPC-1与小鼠mD52可能是重叠基因.对小鼠20种组织器官和不同发育阶段的胚胎组织cDNA的RT-PCR检测证实,该基因主要在前列腺、肾和眼组织中表达,在胃和平滑肌中有少量表达,在其他组织中表达很弱或不表达.而mD52基因则几乎广泛存在于小鼠的各个组织器官中,因此,两个基因虽然序列上高度重叠却是独立调控的.综上所述,mPC-1基因可能是一个与人PC-1基因结构功能类似的新基因.     

表达大肠杆菌K88ac-ST1-LTB融合蛋白基因工程菌株的构建

利用PCR技术,从大肠杆菌C83902质粒中扩增出K88ac基因、ST₁突变基因和LT_B基因,通过分离、纯化、内切酶酶切、连接和转化,构建了含K88ac-ST₁-LT_B融合基因表达载体的重组菌株BL21（DE3）（pXKST3LT5）。经酶切鉴定和DNA序列分析证实,构建的重组质粒pXKST3LT5中含有K88ac-ST₁-LT_B融合基因,且基因序列和阅读框架均正确。经ELISA检测,重组菌株表达的K88ac-ST₁-LT_B融合蛋白能够被ST₁单抗、LTB和K88ac抗体识别。经乳鼠灌胃试验证实,表达的融合蛋白已丧失天然ST₁肠毒素的活性。免疫实验结果表明,K88ac-ST₁-LT_B融合蛋白能够诱发小白鼠产生抗体,该抗体具有中和天然ST₁肠毒素的毒性作用,表明构建的重组菌株可以作为预防仔猪黄、白痢基因工程菌苗的候选菌株。     

菊粉酶高活力菌株的筛选及其产酶研究

利用透明圈法从３０个菊粉酶活力菌株中筛选出两个高活力菌株Ｈ_８和Ｍ_８９,两菌株均鉴定为黑曲霉。Ｈ_８和Ｍ_８９产酶的最佳碳源是菊粉,Ｈ_８最适氮源是（ＮＨ_４）_２ＳＯ_４,Ｍ_８９以草酸胺最好,（ＮＨ_４）_２ＳＯ_４仅次于草酸胺。两菌株产酶的环境条件有一定差异,Ｈ     

异育银鲫GABAB受体1亚基cDNA部分序列的克隆及表达分析

为了确定γ-氨基丁酸B受体（gamma-aminobutyric acid B receptor,GABA_BR）基因在异育银鲫（Carassius auratus gibelio）不同组织中的表达,本实验分别对异育银鲫不同组织中GABA_BR1基因进行RT-PCR扩增,并进行了克隆和测序,在与GenBank基因库中已知GABA_BR1序列进行同源性比对的基础上采用邻接法构建系统发育树,并进一步分析其在异育银鲫不同组织内的表达水平。经克隆获得异育银鲫GABA_BR1基因CDS区序列383 bp,编码127个氨基酸。荧光定量PCR结果显示,GABA_BR1基因在异育银鲫脑、肝、肾、心、肠、鳔、鳃、肌、尾鳍、脾、卵巢、精巢组织中均有表达,且在不同组织中的表达水平由高到低依次是：脑>尾鳍>精巢>心、肠、鳔>卵巢、脾、鳃、肌>肝、肾。本研究证实了GABA_BR1基因在异育银鲫各组织中表达的广泛性,且有明显的组织特异性。     

不同吸入氧浓度联合PCV-VG模式对行腹腔镜膀胱癌根治术的老年患者氧合及肺损伤的影响

摘要 目的：探讨不同吸入氧浓度联合压力控制容量保证通气模式(PCV-VG)对行腹腔镜膀胱癌根治术的老年患者氧合及肺损伤的影响。方法：选择2022年3月至2023年3月在我院拟行全身麻醉下腹腔镜膀胱癌根治术的90例老年膀胱癌患者为研究对象,随机分为A组、B组和C组,各30例。所有患者在PCV-VG模式维持机械通气,其中A组、B组、C组的吸入氧浓度分别为40 %、50 %、60 %。检测所有患者通气前（T0）、通气后1 h、2 h和3h（T1-3）及撤管后0.5 h（T4）时心率（HR）、平均动脉压（MAP）、右心房压（RAP）、动脉血氧分压（PaO₂）,计算氧合指数（PaO₂/FiO₂）、呼吸指数（RI）,记录术后24 h临床肺部感染评分（CPIS）、PACU停留时间、术后住院时间,比较三组手术前及手术结束后血清肺表面活性蛋白A（SP-A）、Clara细胞分泌蛋白（CC16）表达水平及术后肺部并发症发生率。结果：三组在T0、T1、T2、T3和T4时HR、MAP、RAP比较无差异（P>0.05）;在T1、T2、T3和T4时,A组PaO₂、PaO₂/FiO₂均小于B组和C组,RI均大于B组和C组（P<0.05）;而B组与C组在各时间点PaO₂、PaO₂/FiO₂、RI比较无差异（P>0.05）;三组PACU停留时间比较无差异（P>0.05）;B组术后CPIS评分低于A组和C组,术后住院时间短于A组和C组（P<0.05）;C组术后血清SP-A、CC16表达水平均高于A组和B组（P<0.05）;B组术后肺部并发症发生率低于A组和C组（P<0.05）。结论：50%的吸入氧浓度联合PCV-VG模式可有效改善行腹腔镜膀胱癌根治术的老年患者的氧合功能,减轻肺损伤,对于减少术后并发症发生和促进康复具有积极作用,值得临床予以重视。     

通过易错PCR提高鼠伤寒沙门氏菌丙氨酸消旋酶催化活性

[目的] 通过易错PCR技术提高鼠伤寒沙门氏菌中丙氨酸消旋酶的催化活性。[方法] 利用易错PCR技术构建丙氨酸消旋酶基因alr_St的突变体文库,采用缺陷菌株UT5028筛选突变体基因,以D-氨基酸氧化酶偶联法检测各突变蛋白的活性,通过凝胶过滤层析法分析酶蛋白寡聚化状态,并采用HPLC检测酶蛋白的动力学参数。[结果] 经过易错PCR及定点突变技术最终获得了3个催化活性有所提高的突变体A3V、Y343H和A3VY343H,酶学特性分析发现,与野生型蛋白StAlr相比,突变体Y343H仅对底物L/D-丝氨酸的催化效率略有提高,k_cat/K_m值分别是StAlr的2.01和3.68倍;而突变体A3V则对底物L/D-丙氨酸或L/D-丝氨酸的K_m、k_cat和k_cat/K_m值均有较大幅度的改变,其k_cat/K_m值分别是StAlr的105.51、97.36、4.63和10.73倍。凝胶过滤层析结果显示,突变体A3V在蛋白含量极低时就呈现出单体和二聚体共存状态,且随着蛋白含量的增加,其向二聚体状态迁移的速率最为明显。[结论] 丙氨酸消旋酶StAlr的第3位点是影响其催化活性和低聚合状态的关键位点。     

不同水平呼气末正压对老年腹腔镜下结直肠癌根治术患者脑氧供需平衡、炎症因子和脑损伤标志物的影响

摘要 目的：探讨不同水平呼气末正压（PEEP）对老年腹腔镜下结直肠癌根治术患者脑氧供需平衡、炎症因子和脑损伤标志物的影响。方法：选择我院2019年12月-2020年12月收治的90例行腹腔镜下结直肠癌根治术患者，根据随机数字表法分为A组（n=30）、B组（n=30）、C组（n=30），每组均为压力控制容量保证（PCV-VG）模式联合小潮气量加滴定PEEP；其中C组的PEEP值为肺动态顺应性（Cdyn）滴定法下最适PEEP，B组的PEEP=5 cm H₂O，A组的PEEP=0 cm H₂O。对比三组脑氧供需平衡、炎症因子和脑损伤标志物，同时记录三组治疗期间不良反应发生率。结果：气腹后15 min（T1）、停气腹平卧位15 min（T2）时间点，B组、C组颈内静脉血氧饱和度（SjvO₂）、动脉-颈内静脉血氧含量差（AVDO₂）、局部脑组织氧饱和度（rScO₂）高于A组，且C组高于B组同时间点（P<0.05）。术后1 d，B组、C组血清白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平低于A组，且C组低于B组同时间点（P<0.05）。术后1 d，B组、C组血清神经元特异性烯醇化酶（NSE）、S100β低于A组，但C组低于B组同时间点，而脑源性神经营养因子（BDNF）水平高于A组，且C组高于B组同时间点（P<0.05）。三组不良反应发生率组间对比无统计学差异（P>0.05）。结论：Cdyn滴定法下最适PEEP可维持老年腹腔镜下结直肠癌根治术患者脑氧供需平衡，减轻炎症因子分泌，降低脑损伤标志物水平，安全性较好。     

Human monoamine oxidase A and B genes map to xp11.23 and are deleted in a patient with norrie disease

Monoamine oxidase A and B (MAO A and B) are the central enzymes that catalyze oxidative deamination of biogenic amines throughout the body. The regional locations of genes encoding MAO A and B on the X chromosome were determined by using full-length cDNA clones for human MAO A and B, respectively. Using somatic cell hybrids, in situ hybridization, and field-inversion gel electrophoresis as well as deletion mapping in a patient with Norrie disease, we concluded that these two genes are close to each other and to the DXS7 locus (Xp11.3).     

Calcium and Ammonia Stimulate Monoamine Oxidase A Activity in Brain Mitochondria

The effect of ammonia and calcium on the activity of monoamine oxidase (MAO) was studied. The enzyme activity in nonsynaptic brain mitochondria isolated from the rats treated with ammonium acetate was estimated from the release of H₂O₂using spectrophotometry. The effect of calcium on MAO was assayed directly after adding Ca²⁺to the nonsynaptic mitochondria isolated from the forebrain of control rats. Both ammonium acetate injectionin vivoand Ca²⁺additionin vitrostimulated the activity of MAO A but not that of MAO B in mitochondria. This is the first evidence for ammonia and Ca²⁺regulation of MAO A in the forebrain nonsynaptic mitochondria and for their contribution to oxidative stress in the neurons via MAO A activation.     

Oxidation of beta-phenylethylamine by both types of monoamine oxidase: effects of substrate concentration and pH.

β-Phenylethylamine (PEA) was characterized as substrate for both type A and type B monoamine oxidase (MAO) in rat brain mitochondria at different substrate concentrations and at different pHs of the reaction media. The experiments on sensitivity to clorygline and deprenyl showed that the inhibition patterns with PEA as substrate differed markedly at different substrate concentrations: at 10 μM, PEA acted as a specific substrate for type B MAO, but at 50–1000 μM it became a common substrate for both types of MAO. The inhibition patterns were also affected markedly by a small change in pH of the reaction medium, especially when PEA concentrations were 50 and 100 μM: the change in pH from 7.2 to 7.8 resulted in the incresse in the proportion of type A MAO by 20–30 per cent. To investigate the mechanisms of such changes in substrate specificity of PEA, kinetic analyses were carried out at pH 7.2 and 7.8 with the uninhibited, the clorgyline-treated (type B) and the deprenyl-treated (type A) enzyme. The Lineweaver-Burk plots for the uninhibited MAO showed strong substrate inhibition for both pHs, which is more marked at pH 7.8 than at pH 7.2. Pretreatment of the enzyme with 10^?7 M clorgyline resulted in generally similar K_m values for PEA to those of the uninhibited enzyme, and the substrate inhibition at pH 7.8 was also stronger than that at pH 7.2. After pretreatment with 10^?7 M deprenyl, the K_m values were higher and the V_max values were lower than those of the uninhibited or the clorgyline-treated enzyme; there was no or only slight substrate inhibition in these curves. These results suggest that the remarkable changes in substrate specificity observed at different PEA concentrations and at different pHs may be due to the strong substrate inhibition of type B MAO.     

Rasagiline derivatives combined with histamine H3 receptor properties

The irreversible monoamine oxidase B (MAO B) inhibitor rasagiline has been described with multiple disease modifying effects in vitro on models of Parkinson’s disease. The combination of this established drug to recently developed histamine H₃ receptor (H₃R) antagonist elements gives new impetus to the design of multitargeting ligands. Surprisingly, the 5-substituted 3-piperidinopropyloxy rasagiline derivative 1 was more potent on both targets than its 6-substituted isomer. It showed nanomolar affinities at the desired targets (MAO B IC₅₀ = 256 nM; hH₃R K_i = 2.6 nM) with a high preference over monoamine oxidase A (MAO A) and negligible affinity at histamine H₁, H₄, dopamine D₂, D₃ receptors or acetyl-/butyrylcholinesterases.     

[3H]HARMALINE AS A SPECIFIC LIGAND OF MAO A—I. PROPERTIES OF THE ACTIVE SITE OF MAO A FROM RAT AND BOVINE BRAINS

A high-affinity (K_d= 5.9 nM) specific binding site for [³H]harmaline was detected in membranes from rat and bovine brains. Studies of the regional and subcellular distributions of this binding indicated its close association with monoamine oxidase type A activity (MAO A) measured with [³H]serotonin ([³H]5-HT) as the substrate. Maximal binding capacity and MAO A activity were found in mitochondrial enriched fractions. Mitochondria of synaptosomal or extra-synaptosomal origin exhibited very similar properties with respect to [³H]harmaline binding characteristics and MAO A activity. Among psychoactive drugs, only monoamine oxidase inhibitors (MAO I) prevented the specific binding of [₃H]harmaline. Logit-log inhibition curves of binding by MAO I gave only one slope which was not significantly different from 1.0, suggesting the existence of only 1 category of specific sites for [³H]harmaline in the membrane preparations from rat and bovine brains. Consistent with the preferential inhibition of MAO A by harmaline, other MAO I of this class, i.e. clorgyline and Lilly 51641, were 10²-2 × 10³ times more efficient than deprenyl and pargyline, two inhibitors of MAO type B, in displacing [³H]harmaline from its specific binding site. K_i and IC₅₀ values for the inhibition of [³H]harmaline binding by MAO I and MAO substrates (tryptamine, 5-HT, norepinephrine) were almost identical with those characterizing their action on MAO A activity with [³H]5-HT as the substrate. In conclusion, the specific binding site for [³H]harmaline exhibited all the expected properties of the active site of MAO A. Like the technique of precipitation with a specific antibody, binding of [³H]harmaline should be of great help for studying the structural characteristics of the active site of MAO A and determining the number of MAO molecules in tissues under various physiological conditions.     

Influence of culture conditions on monoamine oxidase A and B activity in rat astrocytes

Astroglial cells dispersed from newborn rat hemispheres were established in medium supplemented with 20 per cent fetal calf serum (FBS) and then grown to a confluent monolayer in the presence of 10 per cent FBS or charcoal-stripped FBS (CS). Type 1 astrocytes were subcultured and either maintained under the same conditions of the primary cultures or converted to serum-free chemically defined medium (CDM). No differences were found in either MAO A or MAO B activity of astrocytes grown in the presence of FBS or CS after 15 and 21 days in vitro (day 1 and 6 of subculture). In contrast, on day 21 both MAO A and MAO B activities were markedly higher in astrocytes subcultured in CDM compared with cells maintained in serum-supplemented medium. This difference appeared to be due to increased number of enzyme molecules, since kinetic analysis showed an increase in V_max of both MAO isoenzymes in serum-free medium, but no change in K_m. Consistently, the recovery of MAO A and MAO B activity after irreversible enzyme inhibition by clorgyline and deprenyl was faster in CDM than in FBS-supplemented medium, indicating enhanced enzyme synthesis under serum-free condition. Estimates of half-lives for the recovery of MAO A and MAO B activity indicated that, under both culture conditions, type A activity had a higher turnover rate than type B. The effect of CDM on astrocyte MAO does not appear to be due to selection of a subpopulation of cells, but rather linked to a morphological change (differentiation) with increased synthesis of both MAO isoenzymes.     

Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework

Series of structurally diverse 2-imidazoline derivatives have been synthesized by condensation of substituted aldehydes with ethylenediamine, Pd-catalyzed N-arylation of 2-imidazolines and by the formation of 1,2,4-oxadiazoles and benzoxazepines from 2-imidazoline-containing precursors. The 2-imidazoline derivatives were evaluated as potential inhibitors of human monoamine oxidase (MAO) A and B. Among the 2-imidazolines, good potency inhibitors were discovered with compound 9p (IC₅₀?=?0.012?µM) being the most potent MAO-B inhibitor, while compound 9d (IC₅₀?=?0.751?µM) was the most potent MAO-A inhibitor of the series. These potencies are in the same range as those of reference MAO inhibitors used in the clinic. Among 33 compounds evaluated, 13 exhibited IC₅₀ values in the submicromolar range for the inhibition of an MAO isoform. It is postulated that the imidazoline moieties of some of these inhibitors may be recognized by the imidazoline I₂-binding site of MAO. Good potency MAO inhibitors may be useful for the treatment of neuropsychiatric and neurodegenerative disorders such as depression and Parkinson’s disease, and future application for the treatment of prostate cancer, congestive heart failure and Alzheimer’s disease. In addition, high potency 2-imidazoline-derived MAO inhibitors may be used as potential probes for the imidazoline binding sites of the MAOs, as well as to determine alternative binding regions of imidazoline within the MAO active site.     

Comparative Analysis of Expression of Genes Encoding Enzymes of Catecholamine Catabolism and Renalase in Tissues of Normotensive and Hypertensive Rats

Comparative analysis of expression of genes encoding enzymes of catecholamine catabolism (monoamine oxidases A and B (MAO A and MAO B) and catechol-O-methyl transferase (COMT)) and renalase has been carried out in tissues of normotensive Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). Among investigated tissues the highest level of mRNA of genes encoding key enzymes of catecholamine catabolism (MAO A, MAO B, COMT) was found in the heart of WKY rats. In SHR the mRNA levels of these genes were lower (p < 0.05–0.01), however, no similar changes were observed in the tissues studied in dependence of hypertension. The relative mRNA levels of the studied genes normalized versus actin mRNA significantly varied. In heart and kidney the relative level of COMT mRNA significantly exceeded the relative levels of both MAO A mRNA and MAO B mRNA. In the brain differences in mRNAs of MAOA, MAOB, and COMT were less pronounced. However, in all examined tissue the renalase mRNA level was much (at least 10–20-fold) lower than any other mRNA studied. Taking into consideration known correlations between mRNAs and corresponding protein products reported in the literature for many genes these results suggest that in the case of any catalytic scenarios proposed or even proved for renalase this protein cannot contribute to catecholamine degradation. It is also unlikely that the products of the renalase reaction, β-NAD(P)⁺ and hydrogen peroxide, can exhibit a hypotensive effect due to low expression of the renalase encoding gene.     

1,4-Methylhistamine is a specific substrate for type B monoamine oxidase

1,4-Methylhistamine was characterized as substrate for monoamine oxidase (MAO) in rat liver mitochondria. The $\text{K}$_m and $\text{V}$_max values were 38.8 μM and 6.33 nmoles/mg protein/60 min, respectively. The inhibition experiments with clorgyline and deprenyl, the selective inhibitors for type A and type B MAO, showed that 1,4-methylhistamine was specific for type B MAO.     

Potentiation of Ligand Binding through Cooperative Effects in Monoamine Oxidase B

Crystallographic and biochemical studies have been employed to identify the binding site and mechanism for potentiation of imidazoline binding in human monoamine oxidase B (MAO B). 2-(2-Benzofuranyl)-2-imidazoline (2-BFI) inhibits recombinant human MAO B with a K_i of 8.3 ± 0.6 μm, whereas tranylcypromine-inhibited MAO B binds 2-BFI with a K_d of 9 ± 2 nm, representing an increase in binding energy Δ(ΔG) of −3.9 kcal/mol. Crystal structures show the imidazoline ligand bound in a site that is distinct from the substrate-binding cavity. Contributions to account for the increase in binding affinity upon tranylcypromine inhibition include a conformational change in the side chain of Gln²⁰⁶ and a “closed conformation” of the side chain of Ile¹⁹⁹, forming a hydrophobic “sandwich” with the side chain of Ile³¹⁶ on each face of the benzofuran ring of 2-BFI. Data with the I199A mutant of human MAO B and failure to observe a similar binding potentiation with rat MAO B, where Ile³¹⁶ is replaced with a Val residue, support an allosteric mechanism where the increased binding affinity of 2-BFI results from a cooperative increase in H-bond strength through formation of a more hydrophobic milieu. These insights should prove valuable in the design of high affinity and specific reversible MAO B inhibitors.